QEQLERALNSS TFA

Cat. No.: HY-P3868A: FAQs
Data Sheet Handling Instructions

Molarity Calculator

QEQLERALNSS TFA is a helix B surface peptide (HBSP) derived from erythropoietin with tissue protective activities. QEQLERALNSS TFA protects cardiomyocytes from apoptosis.

For research use only. We do not sell to patients.

QEQLERALNSS TFA Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

QEQLERALNSS TFA is a helix B surface peptide (HBSP) derived from erythropoietin with tissue protective activities. QEQLERALNSS TFA protects cardiomyocytes from apoptosis^[1].

In Vitro

QEQLERALNSS (2.5 and 25 ng/mL; 12 h) clearly decreases TNF-α-induced apoptosis of cardiomyocytes^[1].
QEQLERALNSS (2.5 ng/mL; 5 min) activates critical signaling pathways of cell survival, including Akt, ERK1/2, and STAT3 in cardiomyocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	Cardiomyocytes
Concentration:	2.5 and 25 ng/mL
Incubation Time:	12 h
Result:	Decreased the number of apoptotic cells (≈80% pretreatment, ≈60% without pretreatment) induced by TNF-α (50 pg/mL).

Western Blot Analysis^[1]

Cell Line:	Cardiomyocytes
Concentration:	2.5 ng/mL
Incubation Time:	5 min
Result:	Rapidly activated Akt, ERK1/2, and STAT3 with a peak at 1 min after incubation.

In Vivo

QEQLERALNSS (8 nmol/kg; i.p.; daily for 2 weeks) shows protective effects on ischemia reperfusion and Cyclosporin A (HY-B0579) induced renal injury in rats^[2].
QEQLERALNSS (30 μg/kg; s.c.; three times a week for 6 month) results in a significant decrease in the number of apoptotic cardiomyocytes in the cardiac sections compared with the control in DCM hamsters^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats, renal IR injury model^[2]
Dosage:	8 nmol/kg
Administration:	Intraperitoneal injection, once a day for 2 weeks
Result:	Decreased the level of blood urea nitrogen and tubulointerstitial damage induced by Cyclosporin A (HY-B0579). Reduced apoptotic cells, myeloperoxidase (MPO)+ cells and active caspase-3+ cells.

Molecular Weight

1388.36

Formula

C₅₃H₈₈F₃N₁₇O₂₃

Sequence Shortening

QEQLERALNSS

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

H₂O

Peptide Solubility and Storage Guidelines:

1. Calculate the length of the peptide.

2. Calculate the overall charge of the entire peptide according to the following table:

	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3. Recommended solution:

Overall charge of peptide	Details
Negative (<0)	1. Try to dissolve the peptide in water first. 2. If water fails, add NH₄OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)	1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Ueba H, et al. Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14357-62. [Content Brief]

[2]. Wu Y, et al. Protective effects of HBSP on ischemia reperfusion and cyclosporine a induced renal injury. Clin Dev Immunol. 2013;2013:758159. [Content Brief]

QEQLERALNSS TFA Related Classifications

Cardiovascular Disease

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

QEQLERALNSSApoptosisIschemia reperfusioncyclosporine Amyocardial infarctionheart failureInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks